Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1189-1204

  Garofalo, Antonio ^a,b   Farce, Amaury ^a   Ravez, Séverine ^a,b   Lemoine, Amélie ^a,b   Six, Perrine ^a,b   Chavatte, Philippe ^a   Goossens, Laurence ^a,b   Depreux, Patrick ^a,b  

^a UNIV LILLE   (France)

^b Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(6,7 DIMETHOXY 4 QUINAZOLINYL)OXY]ANILINE; 4 [(6, 7 DIMETHOXY 4 QUINAZOLINYL)OXY] 3 CHLOROANILINE; 4 [(6,7 DIMETHOXY 4 QUINAZOLINYL)OXY] 2 CHLOROANILINE; 4 [(6,7 DIMETHOXY 4 QUINAZOLINYL)OXY] 3 METHYLANILINE; 4 [(6,7 DIMETHOXY 4 QUINAZOLINYL)OXY]ANILINE; 4 CHLORO 6,7 DIMETHOXYQUINAZOLINE; ADENOSINE TRIPHOSPHATE; N (3 BROMOPHENYL) N' [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 2 CHLOROPHENYL]UREA; N (3 BROMOPHENYL) N' [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 3 CHLOROPHENYL]UREA; N (3 BROMOPHENYL) N' [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 3 METHYLPHENYL]UREA; N (3 BROMOPHENYL) N' [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY]PHENYL]UREA; N (3 CHLORO 4 FLUOROANILINO) N' [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 3 METHYLPHENYL]UREA; N (4 BROMOPHENYL) N' [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 3 METHYLPHENYL]UREA; N [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 3 CHLOROPHENYL] N' (2 NAPHTHYL)UREA; N [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY] 3 METHYLPHENYL] N' (2 NAPHTHYL)UREA; N [4 [(6,7 DIMETHOXYQUINAZOLIN 4 YL)OXY]PHENYL] N' (3 METHOXYPHENYL)UREA; PROTEIN KINASE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL PROLIFERATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOLOGICAL PARAMETERS; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINAZOLINES; UREA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84856840782     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2013453     Document Type: Article

References (59)

1. Barton, J.; Blackledge, G.; Wakeling, A. Growth factor and their receptors: new targets for prostate cancer therapy Urology 2001, 58, 114-122 (Pubitemid 32743426)
2. Cohen, P. The role of protein phosphorylation in human health and disease Eur. J. Biochem. 2001, 268, 5001-5010
3. Levitzki, A. Protein kinase inhibitors as a therapeutic modality Acc. Chem. Res. 2003, 36, 462-469
4. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315 (Pubitemid 37361447)
5. Zwick, E.; Bange, J.; Ullrich, A. Receptor tyrosine kinase as targets for anticancer drugs Trends Mol. Med. 2002, 8, 17-22
6. Traxler, P.; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J. Tyrosine kinase inhibitors: from rational design to clinical trials Med. Res. Rev. 2001, 21, 499-512 (Pubitemid 32959239)
7. Traxler, P. Tyrosine kinases as targets in cancer therapy-successes and failures Exp. Opin. Ther. Targets 2001, 21, 499-512
8. Carmeliet, P. Angiogenesis in health and disease Nat. Med. 2003, 9, 653-660 (Pubitemid 36749213)
9. Otrock, Z. K.; Makarem, J. A.; Shamseddine, A. I. Vascular endothelial growth factor family of ligands and receptors: reviews Blood Cells, Mol. Dis. 2007, 38, 258-268 (Pubitemid 46518176)
10. Bishop-Bailey, D. Tumour vascularisation: a druggable target Curr. Opin. Pharmacol. 2009, 9, 96-101
11. Hida, K.; Hida, Y.; Shindoh, M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies Cancer Sci. 2008, 99, 459-466 (Pubitemid 351228561)
12. Otrock, Z. K.; Mahfouz, R. A. R.; Makarem, J. A.; Shamseddine, A. I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms Blood Cells, Mol. Dis. 2007, 39, 212-220 (Pubitemid 47126926)
13. Senger, D. R.; Van de Water, L.; Brown, L. F.; Nagy, J. A.; Yeo, K. T.; Yeo, T. K.; Berse, B.; Jackman, R. W.; Dvorak, A. M.; Dvorak, H. F. Vascular permeability factor (VPF, VEGF) in tumor biology Cancer Metastasis Rev. 1993, 12, 303-324 (Pubitemid 23293287)
14. Roy, H.; Bhardwaj, S.; Ylä-Herttuala, S. Biology of vascular endothelial growth factors FEBS Lett. 2006, 580, 2879-2887 (Pubitemid 43729175)
15. Huang, Z.; Bao, S. D. Roles of main pro- and anti-angiogenic factors in tumor angiogenesis World J. Gastroenterol. 2004, 4, 463-470 (Pubitemid 38325297)
16. Gleadle, J. M.; Ratcliffe, P. J. Hypoxia and the regulation of gene expression Mol. Med. Today 1998, 4, 122-129 (Pubitemid 28155131)
17. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor Endocr. Rev. 1997, 18, 4-25 (Pubitemid 27076453)
18. Roskoski, R., Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit. Rev. Oncol. Hematol. 2007, 62, 179-213
19. Roskoski, R, Jr. VEGF receptor protein-tyrosine kinases: structure and regulation Biochem. Biophys. Res. Commun. 2008, 375, 287-291
20. Shibuya, M.; Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp. Cell Res. 2006, 312, 549-560 (Pubitemid 43290332)
21. Rahimi, N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials Exp. Eye Res. 2006, 83, 1005-1016 (Pubitemid 44397022)
22. Schlessinger, J. Cell signaling by receptor tyrosine kinases Cell 2000, 103, 211-225
23. Hunter, T. Tyrosine phosphorylation: thirty years and counting Curr. Opin. Cell Biol. 2009, 21, 140-146
24. Gibson, K. H.; Grundy, W.; Godfrey, A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines Bioorg. Med. Chem. Lett. 1997, 7, 2723-2728 (Pubitemid 27472818)
25. Kohno, M.; Pouyssegur, J. Targeting the Erk signalling pathway in cancer therapy Ann. Med. 2006, 38, 200-211 (Pubitemid 43675585)
26. Djordjevic, S.; Driscoll, P. C. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases Trends Biochem. Sci. 2002, 27, 426-432 (Pubitemid 34874753)
27. Gourley, M.; Williamson, J. S. Angiogenesis: new targets for the development of anticancer chemotherapies Curr. Pharm. Des. 2000, 6, 417-439 (Pubitemid 30396405)
28. Brunella, C.; Costanza, E. Possible novel targets for therapeutic angiogenesis Curr. Opin. Pharmacol. 2009, 9, 102-108
29. Raffetto, J. D.; Khalil, R. A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease Biochem. Pharmacol. 2008, 75, 346-359 (Pubitemid 350298459)
30. Hida, K.; Hida, Y.; Shindoh, M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies Cancer Sci. 2008, 99, 459-466 (Pubitemid 351228561)
31. Masood, R.; Kundra, A.; Zhu, S.; Xia, G.; Scalia, P.; Smith, D. L.; Gill, P. S. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops Int. J. Cancer 2003, 104, 603-610 (Pubitemid 36337260)
32. Booy, E. P.; Johar, D.; Maddika, S.; Pirzada, H.; Sahib, M. M.; Gehrke, I.; Loewen, S.; Louis, S. F.; Kadkhoda, K.; Mowat, M.; Los, M. Monoclonal and bispecific antibodies as novel therapeutics Arch. Immunol. Ther. Exp. 2006, 54, 85-101 (Pubitemid 44257346)
33. Ferrara, N.; Hillan, K. J.; Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem. Biophys. Res. Commun. 2005, 333, 328-335 (Pubitemid 40848295)
34. Scanga, A.; Kowdley, K. Sorafenib: a glimmer of hope for unresectable hepatocellular carcinoma? Hepathology 2009, 49, 332-334
35. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M. Sorafenib in advanced clear-cell renal-cell carcinoma N. Eng. J. Med. 2009, 49, 332-334
36. Motzer, R. J.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Figlin, R. A.; Ginsberg, M. S.; Kim, S. T.; Baum, C. M.; DePrimo, S. E.; Li, J. Z.; Bello, C. L.; Theuer, C. P.; George, D. J.; Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J. Clin. Oncol. 2006, 24, 16-24 (Pubitemid 46630489)
37. Ryan, A. J.; Wedge, S. R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase Br. J. Cancer 2005, 92, S6-S13
38. Ciardiello, F.; Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, D.; De Vita, F.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin. Cancer Res. 2004, 10, 784-793 (Pubitemid 38174017)
39. Morabito, A.; Piccirillo, M. C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions Oncologist 2009, 14, 378-390
40. Garofalo, A.; Goossens, L.; Lemoine, A.; Farce, A.; Arlot, Y.; Depreux, P. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer J. Enzyme Inhib. Med. Chem. 2010, 25, 158-171
41. Pandey, A.; Volkots, D. L.; Seroogy, J. M.; Rose, J. W.; Yu, J. C.; Lambing, J. L.; Hutchaleelaha, A.; Hollenbach, S. J.; Abe, K.; Giese, N. A.; Scarborough, R. M. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family J. Med. Chem. 2002, 45, 3772-3793 (Pubitemid 34856116)
42. Garofalo, A.; Goossens, L.; Lemoine, A.; Ravez, P.; Six, P.; Howsam, M.; Farce, A.; Depreux, P. (4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl) carbamic acid ester: a novel series of dual EGFR/VEGFR-2 receptor tyrosine kinase inhibitors MedChemComm 2011, 2, 65-72
43. Garofalo, A.; Goossens, L.; Farce, A.; Lemoine, A.; Ravez, P.; Six, P.; Depreux, P. Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2106-2112
44. Furuta, T.; Sakai, T.; Senga, T.; Osawa, T.; Kubo, K.; Shimizu, T.; Suzuki, R.; Yoshino, T.; Endo, M.; Miwa, A. Identification of potent and selective inhibitors of PDGF Receptor autophosphorylation J. Med. Chem. 2006, 49, 2186-2192
45. Desroses, M.; Laconde, G.; Depreux, P.; Hénichart, J. P. Synthesis of unsymmetrical dialkoxy quinazolines Org. Prep. Proced. Int. 2004, 36, 445-452 (Pubitemid 39531415)
46. Telliez, A.; Desroses, M.; Pommery, N.; Briand, O.; Farce, A.; Laconde, G.; Lemoine, A.; Depreux, P.; Hénichart, J. P. Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells ChemMedChem 2007, 2, 318-332
47. Garofalo, A.; Goossens, L.; Lebegue, N.; Depreux, P. A novel and efficient one-pot synthesis of (aminophenyl)carbamic acid ester Synth. Commun. 2011, 41, 2007-2016
48. Elliott, R. D.; Thomas, H. J.; Shaddix, S. C.; Adamson, D. J.; Brockman, R. W.; Riordan, J. M.; Montgomery, J. A. Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis J. Med. Chem. 1988, 31, 250-254 (Pubitemid 18027881)
49. Garofalo, A.; Goossens, L.; Baldyrou, B.; Lemoine, A.; Ravez, S.; Six, P.; David-Cordonnier, M. H.; Bonte, J. P.; Depreux, P.; Lansiaux, A.; Goossens, J. F. Design, synthesis and DNA-binding of N-alkyl(anilino)quinazoline derivatives J. Med. Chem. 2010, 53, 8089-8103
50. SYBYL 6.9.1; Tripos Inc.: St. Louis, MO, 2003.
51. Clark, M.; Cramer, R. D., III; van Opdenbosch, N. Validation of the general purpose Tripos 5.2 force field J. Comput. Chem. 1989, 10, 982-1012
52. Berman, H. M.; Westbrook, J.; Feng, Z.; Gary, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
53. Miyazaki, Y.; Matsunaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Philippe, R. J.; Shibahara, M.; Liu, W.; Sato, H.; Wang, L.; Nolte, R. T. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 2203-2207 (Pubitemid 40523073)
54. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748 (Pubitemid 27170693)
55. Wang, R.; Lai, L.; Wang, S. J. Further development and validation of empirical scoring functions for structure-based binding affinity prediction J. Comput.-Aided Mol. Des. 2002, 16, 11-26 (Pubitemid 34855041)
56. Oprea, T. I.; Waller, C. L.; Marshall, G. R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes J. Med. Chem. 1994, 37, 2206-2215 (Pubitemid 24228449)
57. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 1988, 110, 5959-5967
58. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity J. Med. Chem. 1994, 37, 4130-4146 (Pubitemid 24379702)
59. Clark, M.; Cramer, R. D., III. The probability of chance correlation using partial least squares (PLS) Quant. Struct.-Act. Relat. 1993, 12, 137-145 (Pubitemid 23203836)